TY  - GEN
AU  - Trimble,Cornelia L
AU  - Morrow,Matthew P
AU  - Kraynyak,Kimberly A
AU  - Shen,Xuefei
AU  - Dallas,Michael
AU  - Yan,Jian
AU  - Edwards,Lance
AU  - Parker,R Lamar
AU  - Denny,Lynette
AU  - Giffear,Mary
AU  - Brown,Ami Shah
AU  - Marcozzi-Pierce,Kathleen
AU  - Shah,Divya
AU  - Slager,Anna M
AU  - Sylvester,Albert J
AU  - Khan,Amir
AU  - Broderick,Kate E
AU  - Juba,Robert J
AU  - Herring,Timothy A
AU  - Boyer,Jean
AU  - Lee,Jessica
AU  - Sardesai,Niranjan Y
AU  - Weiner,David B
AU  - Bagarazzi,Mark L
TI  - Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
SN  - 1474-547X
PY  - 2016///0113
KW  - Adult
KW  - Cancer Vaccines
KW  - immunology
KW  - DNA-Binding Proteins
KW  - genetics
KW  - Double-Blind Method
KW  - Female
KW  - Human papillomavirus 16
KW  - Human papillomavirus 18
KW  - Humans
KW  - Oncogene Proteins, Viral
KW  - Papillomavirus E7 Proteins
KW  - Papillomavirus Infections
KW  - drug therapy
KW  - Papillomavirus Vaccines
KW  - Repressor Proteins
KW  - Treatment Outcome
KW  - Uterine Cervical Neoplasms
KW  - Vaccines, DNA
KW  - Young Adult
KW  - Uterine Cervical Dysplasia
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(15)00239-1
ER  -